Development of a sensitive and specific assay system for cholecystokinin tetrapeptide

Peptides

Volumn 18, Issue 6, 1997, Pages 869-875

  Merani, S ^a   Palmour, R M ^a   Bradwejn, J ^b   Berezowska, I ^e   Vaccarino, F J ^b,c   Gutkowska, J ^d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Hôtel Dieu Hospital ^*

Author keywords

Anxiety; Bolton Hunter; CCK 4; CCK 8ns; CCK 8s; Cholecystokinin; Healthy volunteers; HPLC; Panic attacks; Plasma levels; Radioimmunoassay; RIA

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; DESULFOCHOLECYSTOKININ OCTAPEPTIDE; IODINE 125; TETRAGASTRIN; TETRAGASTRIN DERIVATIVE; THYROGLOBULIN;

ADULT; ARTICLE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PEPTIDE ANALYSIS; PLASMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVERSED PHASE LIQUID CHROMATOGRAPHY;

EID: 0030822187     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00007-7     Document Type: Article

References (43)

1. Ballenger A. B., Clark M. L. L-Phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: Evidence for a physiological role of CCK in control of eating. Metabolism. 43:1994;735-738.
2. Beinfeld M. C., Meyer D. K., Eskay R. L., Jensen R. T., Brownstein M. J. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res. 212:1981;51-57.
3. Bradwejn J., Koszycki D., Cöuetoux du Tertre A., Bourin M., Palmour R., Ervin F. The cholecystokinin hypothesis of panic and anxiety disorders: a review. J. Psychopharmacol. 6:((3)):1992;345-351.
4. Bradwejn J., Koszycki D., Bourin M. Dose ranging study of the effect of CCK-4 in healthy volunteers. J. Psychiatry Neurosci. 16:1991;260-264.
5. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin-tetrapeptide induced panic attacks in patients with panic disorder. Can. J. Psychiatry. 35:1990;83-85.
6. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch. Gen. Psychiatry. 48:1991;603-607.
7. Cantor P. Cholecystokinin in plasma. Digestion. 42:1989;181-201.
8. Cantor P., Rehfeld J. F. The molecular nature of cholecystokinin in human plasma. Clinica. Chimica. Acta. 168:1987;153-158.
9. Crawley J. N., Corwin R. L. Biological actions of cholecystokinin. Peptides. 15:((4)):1994;731-755.
10. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy subjects. Arch. Gen. Psychiatry. 46:1989;511-517.
11. Eberlein G. A., Eysselein V. E., Davis M. T., Lee T. D., Shively J. E., Grandt D., Niebel W., Williams R., Moessner J., Zeeh J., Meyer H. E., Goebell H. Jr., Reeve J. R. Patterns of prohormone processing. J. Biol. Chem. 267:1992;1517-1521.
12. Eberlein G. A., Eysselein V. E., Hesse W. H., Goebell H., Schaeffer M., Reeve J. R. Jr. Detection of cholecystokinin -58 in human blood by inhibition of degradation. Am. J. Physiol. 253:1987;G477-G482.
13. Geracioti T. D. Jr., Nicholson W. E., Orth D. N., Ekhator N. N., Loosen P. T. Cholecystokinin in human cerebrospinal fluid: Concentrations, molecular forms and relationship to fasting and feeding in health, depression and alcoholism. Brain Res. 629:1993;260-268.
14. Han J. S. Cholecystokinin octapeptide (CCK-8): A negative feedback control mechanism for opioid analgesia. Prog. Brain Res. 105:1995;263-271.
15. Harper A. A., Raper H. S. Pancreoenzyme, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine. J. Physiol. (London). 102:1943;115-125.
16. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. TiPS. 14:1993;244-249.
17. Höcker M., Schmidt W. E., Creutzfeldt W., Choudury A. R., Nustede R., Schafmayer A., Fölsch U. R. Determination of plasma (CCK) concentrations by bioassay and radioimmunoassay in man. A critical evaluation. Regul. Pept. 37:1992;255-269.
18. Ivy A. C., Oldberg E. A hormone mechanism of gallbladder contraction and evacuation. Am. J. Physiol. 86:1928;599-613.
19. Jansen J. B. M. J., Lamers C. B. H. W. Molecular forms of cholecystokinin in plasma from normal and gastrectomized human subjects following a fat meal. Peptides. 8:1987;801-805.
20. Koulischer D., Moroder L., Deschodt-Lanckman M. Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro. Regul. Pept. 4:1982;127-139.
21. Lemaire M., Böhme G. A., Piot O., Roques B. P., Blanchard J.C. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology. 115:1994;435-440.
22. Lemaire M., Piot O., Roques B. P., Böhme G. A., Blanchard J.C. Evidence for an endogenous cholecytokininergic balance in social memory. Neuroreport. 3:((10)):1992;929-932.
23. Liddle R. A., Goldfine I. D., Rosen M. S., Taplitz R. A., Williams J. A. Cholecystokinin bioactivity in human plasma. J. Clin. Invest. 75:1985;1144-1152.
24. Lieverse R. J., Jansen J. B. M. J., Masclee A. A. M., Lamers C. B. H. W. Satiety effects of cholecystokinin in humans. Gastroenterology. 106:1994;1451-1454.
25. Lydiard R. B. Neuropeptides and anxiety: focus on cholecystokinin. Clin. Chem. 40:((2)):1994;315-318.
26. Lydiard R. B., Ballenger J. C., Laraia M. T., Fossey M. D., Beinfeld M. C. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am. J. Psychiatry. 149:1992;691-693.
27. Lydiard R. B., Brewerton T. D., Fossey M. D., Laraia M. T., Stuart G., Beinfeld M. C., Ballenger J. C. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am. J.Psychiatry. 150:1993;1099-1101.
28. Merani, S.; Dam, T. V.; Palmour, R.; Ervin, F. R.; Gutkowska, J. Autoradiographic quantification of cholecystokinin receptors in cardiomyopathic and syrian hamster brain. Abstract In: Society for Neuroscience; Nov., 1996.
29. Miller L. J., Jardine J., Weissman E., Go V. L. W., Speicher D. Characterization of cholecystokinin from the human brain. J. Neurochem. 43:1984;835-840.
30. Miyasaka K., Kanai S., Ohta M., Kawanami T., Kono A., Funakoshi A. Lack of satiety effect of cholecystokinin (CCK) in a new rat model not expressing the CCK-A receptor gene. Neurosi. Letters. 180:1994;143-146.
31. Mutt V., Jorpes J. E. Hormonal polypeptides of the upper intestine. Biochem. J. 125:1971;57-58.
32. Noble F., Smadja C., Roques B. P. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists. J. Pharmacol. Exp. Ther. 271:((3)):1994;1127-1134.
33. Pauwels S., Najdovski T., Dimaline R., Lee C. M., Deschodt-Lanckman M. Degradation of human gastrin and CCK by endopeptidase 24.11: Different behavior of the sulfated and unsulfated peptides. Biochim. Biophys. Acta. 996:1989;82-88.
34. Pavlasevic S., Bednar I., Qureshi G. A., Södersten P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport. 5:((3)):1993;225-228.
35. Skowsky W. R., Fisher D. A. The use of thyroglobulin to induce antigenicity to small molecules. J. Lab. Clin. Med. 80:((1)):1972;134-144.
36. Suh H. W., Kim Y. H., Choi Y. S., Song D. K. Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse. Peptides. 16:((7)):1995;1229-1234.
37. Takahishi Y., Kato K., Hayashizaki Y., Wakabayashi T., Ohtsuka E., Matsuki S., Ikehara M., Matsubara K. Molecular cloning of the cholecystokinin gene by use of a synthetic probe containing deoxyinosine. Proc. Natl. Acad. Sci. USA. 82:1985;1931-1935.
38. Tokunga Y., Cox K. L., Coleman R., Concepcion W., Nakazato P, Esquivel C. O. Characterization of cholecystokinin receptos on the human gallbladder. Surgery. 113:1993;155-162.
39. 125I polypeptide hormones for radioimmunoassay using glucose oxidase with lactoperoxidase. Life Sci. 21:1977;959-966.
40. Vaitukaitis J., Robbins J. B., Nieschlag E., Ross G. T. A method for producing specific antisera with small doses of immunogen. J. Clin. Endocrinol. Metab. 33:((6)):1971;988-991.
41. Vinayek R., Jensen R. T., Gardner J. D. Role of sulfate ester in influencing biological activity of cholecystokinin-related peptides. Am J. Physiol. 252:1987;G178-G181.
42. Walsh J. H., Lamers C. B., Valenzuela J. E. Cholecystokinin-octapeptide immunoreactivity in human plasma. Gastroenterology. 82:1982;438-444.
43. Wisniewska R. J., Wisniewski K. Cholecystokinin (CCK) and C-terminal fragments of CCK-effects of CCK-33, CCK-8 and CCK-4 in the cardiovascular system of diabetic rats. Gen. Pharmacol. 27:((2)):1996;399-405.